Jablonec Nad Nisou 1

Researchers are evaluating orforglipron to measure its effects on cardiovascular outcomes in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This phase 3 study aims to compare orforglipron with a placebo to better understand its impact on major cardiovascular events over about five years. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally along with standard care. The study is double-blinded, meaning neither participants nor researchers will know who receives the active drug or placebo during the trial period. During the study, participants will be followed for around five years, with researchers monitoring the time to the first major cardiovascular event and additional outcomes such as cardiovascular and kidney events, changes in kidney function measured by eGFR, and the onset of type 2 diabetes. The study includes regular assessments to track these outcomes and ensure participant safety throughout the long-term follow-up.

Researchers are evaluating whether the combination of vicadrostat BI 690517 and empagliflozin helps adults with heart failure who have symptoms and a left ventricular ejection fraction LVEF of 40% or more. This phase III study is designed to compare the effects of vicadrostatempagliflozin tablets versus placeboempagliflozin tablets on heart failure outcomes. The study aims to understand if this combined treatment improves health and reduces heart-related events. Participants are randomly assigned to one of two groups one group takes vicadrostat plus empagliflozin tablets once a day, and the other takes placebo plus empagliflozin tablets once a day. The study has no fixed duration and continues as long as participants benefit and tolerate the treatment. Throughout the study, participants visit their doctors regularly for health checks, and study staff may also contact them by phone to monitor well-being and any side effects. During the study, researchers monitor participants health through regular doctor visits and phone contacts. They collect data on heart-related events such as cardiovascular death, hospitalizations for heart failure, and urgent visits for heart failure over up to 42 months. Participants also answer questions about their symptoms and well-being. The study carefully tracks safety and treatment tolerance while gathering information to determine if the combined treatment helps people with heart failure.

This research aims to evaluate the software Lipidica 1.0, designed to process lipidomic data from an in-house diagnostic device, for screening pancreatic cancer PaC in people at high risk due to family history, gene mutations, or hereditary pancreatic diseases. Pancreatic cancer often has a poor prognosis due to late detection and rapid progression. Early screening in high-risk groups may improve outcomes, and this study builds on previous findings showing distinct lipid profiles in pancreatic cancer patients. Participants are divided into two groups those with confirmed resectable pancreatic cancer, who will have one baseline visit for blood sampling to analyze lipid profiles and tumor markers and those at high risk without cancer, who will have two or three visits over up to 12 months. The high-risk group undergoes blood tests and medical imaging such as endoscopic ultrasonography, magnetic resonance, or computed tomography. The softwares ability to distinguish between cancer patients and high-risk individuals without cancer is the main focus. Participants will attend visits for blood collection and imaging at the start and end of the study, with some having an additional visit based on initial results. Blood tests include lipidomic analysis, tumor markers CA 19-9 and CEA, HbA1c, and hCG for women of childbearing potential. Imaging assessments occur up to three times per participant. Researchers will analyze these data to verify the softwares performance in differentiating disease presence. The study is expected to continue for about three years, with interim analysis after one year.

Overactive bladder OAB is a common health issue affecting 15-20% of adults, but less than half seek medical help. This research aims to raise awareness of OAB and improve referrals to specialists who can provide appropriate diagnosis and treatment. The project is led by the Institute of Health Information and Statistics of the Czech Republic and focuses on early detection and reducing the negative impact of OAB on quality of life. The study uses an online screening tool available via a web platform and mobile app, where participants complete validated questionnaires related to OAB symptoms, personal and family history, and quality of life. Those with positive screening results are offered an examination by specialists such as gynecologists, urogynaecologists, or urologists. Specialists access participant profiles through the platform, confirm or rule out OAB, perform additional diagnostic tests if needed, and set up standard treatments. Participation requires consent to data processing under GDPR. Participants will provide data through the online tool and may attend follow-up examinations with specialists. The study tracks outcomes including the number of participants completing the screening, those agreeing to specialist visits, confirmed diagnoses, and follow-up attendance over an average period of six to nine months. Data collected will evaluate the pilot projects effectiveness and cost, with all information stored securely respecting privacy regulations.